Annovis Bio, Inc.

NYSE:ANVS

Biotechnology

Healthcare
$1.21 +0.00%

+$0.00 today

Market cap
$51.64M
Beta
1.24
P/E (TTM)
-1.1
EPS (TTM)
-$1.47
52W Low $1.54High $5.50

Volume 1.35M

Average 1.08M

ANVS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Annovis Bio, Inc.NYSE: ANVS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 27.85M shares rose 128.6% year over year, ahead of the +82.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 12.2% from the prior quarter. Over 3 fiscal years it compounded at +36.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +128.6% holds above the trailing-twelve-month pace of +82.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
27.85M+12.2% QoQ
Last fiscal yearDec 2025
20.55M+68.7% YoY
LTMMar 2026
22.96M+82.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+128.6%——
1 year+68.7%——
3-year CAGR+36.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
20.55M USD
Year-over-year change
+68.7%
4-year CAGR
+28.1%

Weighted Avg Shares vs competitors

How ANVS compares with its peers on the latest reported figures

  • ANVS's LTM Mar 2026 weighted avg shares of 22.96M shares is the 5th highest of the 6 companies compared; the peer median is 31.26M shares.
  • Its year-over-year change of +82.7% is the 2nd highest of 6, against a peer median of +27.8%.
  • Over three fiscal years its annual growth of +36.0% compares with a peer median of +22.3%.
ANVS Competitors Peer median
Weighted Avg Shares for ANVS and competitors
Company Period LTM YoY 3-year CAGR
PDSBPDS Biotechnology CorporationLTM Mar 202648.66M +29.4%+17.5%
MAIAMAIA Biotechnology, Inc.LTM Mar 202631.93M +27.8%+51.3%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 202631.26M +0.3%+8.9%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+22.3%
ANVSAnnovis Bio, Inc.LTM Mar 202622.96M +82.7%+36.0%
PYPDPolyPid Ltd.LTM Mar 202618.85M +145.8%+132.8%
Peer median (excluding ANVS) 31.26M+27.8%+22.3%

Competitors are the stored peer set for ANVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development8.48M16.52M38.79M20M25.22M
Selling, General & Admin6.06M9M6.24M6.7M4.48M
Operating Expenses14.54M25.51M45.04M26.69M29.7M
Depreciation & Amortization00000
EBITDA(14.5M)(25.33M)(56.2M)(22.74M)(28.85M)
EBITDA Margin—————
Operating Income(14.54M)(25.51M)(45.04M)(26.69M)(29.7M)
Operating Margin—————
Interest Income13.34K182.71K667.9K331.85K699.06K
Interest Expense0001.85M0
Other Income / Expenses50.09K182.71K(11.17M)2.1M841.06K
Income Before Tax(14.49M)(25.33M)(56.2M)(24.59M)(28.85M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(14.49M)(25.33M)(56.2M)(24.59M)(28.85M)
Net Margin—————
EPS (Basic)(1.90)(3.10)(6.23)(2,018.50)(1.40)
EPS (Diluted)(1.90)(3.10)(6.23)(2,009.77)(1.40)
Weighted Avg Shares7.63M8.16M9.02M12.18M20.55M
Weighted Avg Shares (Diluted)7.63M8.16M9.02M12.24M20.55M

Annovis Bio, Inc.

NYSE:ANVS

Intrinsic Alpha fair value

Locked

Current Price

$1.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.